NAD+ (Nicotinamide Adenine Dinucleotide)

Research Summary

Mechanism & Physiological Role

Coenzyme in the mitochondrial electron transport chain and an obligate substrate for sirtuins (SIRT1-7) and PARP enzymes involved in DNA repair, genomic stability, and metabolic signaling.

Clinical & Research Applications

Discussed in the peer-reviewed literature in the context of cellular energy metabolism, cognitive research, longevity studies, and substance-use recovery research.

Biosynthesis, Handling & Sourcing

NAD+ is maintained by three biosynthetic routes rather than one: de novo synthesis from tryptophan by way of quinolinic acid, the Preiss-Handler pathway from nicotinic acid, and a salvage pathway that recycles nicotinamide through nicotinamide phosphoribosyltransferase. The salvage route carries most of the flux in mammalian tissue, which is why the intracellular pool turns over on a timescale of hours rather than days, and why precursor availability rather than total body content is what the literature tends to measure.

The molecule occupies two distinct roles that are easy to conflate. As a redox cofactor it cycles between NAD+ and NADH without net consumption, shuttling electrons through glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation. As a substrate it is cleaved and consumed, releasing nicotinamide, by three enzyme families: the sirtuins, the poly(ADP-ribose) polymerases recruited to DNA strand breaks, and the ectoenzyme CD38. Because all three draw on the same pool, their activities are coupled, and that coupling is the subject of an extensive peer-reviewed literature on cellular ageing.

For a compounding pharmacy the governing constraints are chemical rather than pharmacological. NAD+ in aqueous solution is sensitive to light and to alkaline pH, and it degrades to nicotinamide and ADP-ribose under both, so sterile preparations are compounded under USP General Chapter 797, protected from light, and carry a beyond-use date assigned at preparation rather than a manufacturer expiry. Practices sourcing it should confirm storage conditions and in-use dating for the specific container format at account setup, because whichever of those limits expires first is the one that governs.

The research position is worth stating precisely rather than generously. Injectable and intravenous NAD+ has been studied in small human cohorts alongside a much larger body of preclinical work, and reviews in the peer-reviewed literature describe the pharmacokinetics of NAD+ and its precursors as an open question rather than a settled one. Nothing on this page is a statement that any preparation is suitable for a given patient. Compounded medications are not FDA-approved finished drug products.